$8M for NKT Therapeutics
Rebecca Zacks3/16/09
NKT Therapeutics, a Newton, MA-based startup built around technology from Boston’s Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, announced it has raised $8 million in a Series A financing led jointly by SV Life Sciences and MedImmune Ventures. NKT, whose website says the financing closed in December 2008, is developing treatments for asthma, cancer, autoimmune diseases, and other ailments by targeting natural killer T cells, a type of white blood cell.
Today’s Financings and Deals: Innovatis, NKT Therapeutics, SFJ Pharma | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries
3/16/09 8:57 pm
[...] -NKT Therapeutics announced that it received $8M in venture financing from SV Life Sciences and MedImmune Ventures. NKT is developing an antibody that targets the invariant T cell receptor which, depending on the effector function of the antibody, can either activate or deplete NKT cells. NKT plans to target asthma as well as cancer, autoimmune diseases, atopic dermatitis and vaccine adjuvants. [Xconomy] [...]